Peptide-Based Drug Design

Analysis of Aβ Interactions 85
9. Harper, J.D., Wong, S.S., Lieber, C.M. and Lansbury, P.T. (1997) Observation of
metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4,
119–125.
10. Relini, A., Torrassa, S., Rolandi, R., et al. (2004). Monitoring the process of
HypF fibrillization and liposome permeabilization by protofibrils. J. Mol. Biol. 338,
943–957.
11. Hartley, D.M., Walsh, D.M., Ye, C.P., et al. (1999) Protofibrillar intermediates of
amyloid beta-protein induce acute electrophysiological changes and progressive
neurotoxicity in cortical neurons.J.Neurosci. 19, 8876–8884.
12. Behl, C., Davis, J.B., Lesley, R. and Schubert, D. (1994) Hydrogen peroxide
mediates amyloid beta protein toxicity. Cell 77, 817–827.
13. Ambroggio, E.E., Kim, D.H., Separovic, F., et al. (2005) Surface behavior and
lipid interaction of Alzheimer beta-amyloid peptide 1–42: a membrane-disrupting
peptide. Biophys. J. 88, 2706–2713.
14. Mattson, M.P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I. and Rydel, R.E.
(1992) beta-Amyloid peptides destabilize calcium homeostasis and render human
cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376–389.
15. Curtain, C.C., Ali, F., Volitakis, I., et al. (2001) Alzheimer’s disease amyloid-beta
binds copper and zinc to generate an allosterically ordered membrane-penetrating
structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276,
20466–20473.
16. Dong, J., Atwood, C.S., Anderson, V.E., et al. (2003) Metal binding and oxidation
of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence.
Biochemistry 42, 2768–2773.
17. Pike, C.J., Walencewicz-Wasserman, A.J., Kosmoski, J., Cribbs, D.H., Glabe, C.G.
and Cotman, C.W. (1995) Structure-activity analyses of beta-amyloid peptides:
contributions of the beta 25–35 region to aggregation and neurotoxicity. J.
Neurochem. 64, 253–265.
18. Arispe, N., Rojas, E. and Pollard, H.B. (1993) Alzheimer disease amyloid beta
protein forms calcium channels in bilayer membranes: blockade by tromethamine
and aluminum. Proc. Natl. Acad. Sci. USA 90, 567–571.
19. Guo, Q., Fu, W., Xie, J., et al. (1998) Par-4 is a mediator of neuronal degeneration
associated with the pathogenesis of Alzheimer disease. Nat. Med. 4, 957–962.
20. Wiesner, A. (2004) Detection of tumor markers with ProteinChip technology. Curr.
Pharm. Biotechnol. 5, 45–67.
21. Austen, B.M., Frears, E.R. and Davies, H. (2000) The use of seldi proteinchip arrays
to monitor production of Alzheimer’s betaamyloid in transfected cells. J. Pept. Sci.
6, 459–469.
22. Bradbury, L.E., LeBlanc, J.F. and McCarthy, D.B. (2004) ProteinChip array-based
amyloid beta assays. Methods Mol. Biol. 264, 245–257.
23. Maddalena, A.S., Papassotiropoulos, A., Gonzalez-Agosti, C., et al. (2004)
Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer’s
disease determined by protein biochip technology. Neurodegener. Dis. 1,
231–235.